急性冠脉综合征初期不同剂量阿托伐他汀短期治疗对炎症因子的影响

目的:观察急性冠脉综合征患者初期给予不同剂量阿托伐他汀短期治疗对白介素-6、高敏C-反应蛋白的影响,探讨急性冠脉综合征初期患者应用他汀类药物的必要性和有效性.方法:71例急性冠脉综合征患者随机分为阿托伐他汀40 mg治疗组(26例)、阿托伐他汀20 mg治疗组(25例)和对照组(20例),测定治疗前后血清白介素-6、高敏C-反应蛋白水平及血脂、肝功等指标.结果:①3组病例治疗前后血脂各项指标变化差异均无显著性(P＞0.05).②阿托伐他汀40 mg治疗组和20 mg治疗组治疗后白介素-6和高敏C-反应蛋白水平均明显下降,与治疗前比较差异均有显著性(P＜0.05),与对照组治疗后比较差异亦有显著性(P＜0.05).③阿托伐他汀40 mg治疗组白介素-6和高敏C-反应蛋白水平治疗后下降更明显,与阿托伐他汀20 mg治疗组比较差异有显著性(P＜0.05).结论:急性冠脉综合征患者初期给予阿托伐他汀短期治疗,可明显降低炎症因子水平,对稳定冠脉粥样斑块有利,且剂量偏大可能获得更大的益处.

The short-term effect of different dose of atorvastatin on inflammatory factors in patients with acute coronary syndrome

OBJECTIVE To observe the influence of different dose of atorvastatin on IL-6 and CRP in patients with acute coronary syndrome (ACS) within the first 3 days after the coronary events. METHODS Seventy-one patients with ACS were divided randomly into atorvastatin 40 mg group, atorvastatin 20 mg group and control group. Levels of IL-6 , CRP and lipid were detected before and after treatment. RESULTS Levels of lipid were not changed significantly in the three groups ( P > 0.05 ). Levels of Il-6 and CRP decreased significantly in both atorvaststin 40 mg group and atorvaststin 20 mg group than these in the control group ( P < 0.05 ), but these changes were more significant in the atorvaststin 40 mg group than in the atorvastatin 20 mg group ( P < 0.05 ).CONCLUSION Atorvastatin could decrease the levels of inflammatory factors in patients with ACS within the first 3 days after the attack of this coronary event. Therefore it may be benefit to stabilize atherosclerotic plaque.The higher dose,the more benefit.